A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension

被引:35
作者
Thase, Michael E. [1 ]
Haight, Barbara R. [2 ]
Johnson, Marty C. [2 ]
Hunt, Thomas [3 ]
Krishen, Alok [2 ]
Fleck, Richard J. [2 ]
Modell, Jack G. [2 ]
机构
[1] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA
[2] GlaxoSmithKline Inc, Res Triangle Pk, NC USA
[3] MetaTrials Inc, Austin, TX USA
关键词
D O I
10.1097/JCP.0b013e318172424e
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of bupropion on blood pressure and heart rate were evaluated in a double-blind, placebo-controlled study of community volunteers with untreated mild (stage 1) hypertension (systolic blood pressure [SBP],. 140-159 min Hg, and/or diastolic blood pressure, 90-99 min Hg). Three hundred subjects were randomly assigned (1:1:1:1) to 4 weeks of placebo or bupropion sustained release (SR) 150 300, or 400 mg/d. Mean clinical blood pressures decreased from baseline to the end of protocol in all groups (n = 296): -6.53 -6.46, -4.20, -4.87 min Hg for SBP; and -2.36, -2.27, -1.95, -1.55 mm Hg for diastolic blood pressure. for each group, respectively. Although decreases in mean clinical blood pressure were observed in all groups, the reduction in SBP was less on bupropion SR 300 mg/d than on placebo (-4.20 vs -6.53 mm Ha, respectively; Delta = 2.33, P = 0.020). Neither mean 24-hour ambulatory blood pressure measurements nor the proportion of subjects with clinically significant increases in blood pressure differed between any bupropion SR dose and placebo. Mean heart rate increases were small but statistically significant at 400 mg/d versus placebo (2.28 vs -0.64 beats/min; Delta = 2.92, P = 0.004). Although only minor effects on blood pressure were observed in this trial, an infrequent association of bupropion therapy and treatment-emergent hypertension cannot be ruled out.
引用
收藏
页码:302 / 307
页数:6
相关论文
共 18 条
  • [1] Tolerability and safety of sustained-release bupropion in the management of smoking cessation
    Aubin, HJ
    [J]. DRUGS, 2002, 62 (Suppl 2) : 45 - 52
  • [2] Bupropion exposures: Clinical manifestations and medical outcome
    Belson, MG
    Kelley, TR
    [J]. JOURNAL OF EMERGENCY MEDICINE, 2002, 23 (03) : 223 - 230
  • [3] CLAYTON AH, 2003, PRIM PSYCHIAT, V10, P55
  • [4] CLYBURN EB, 1995, SEMIN NEPHROL, V15, P72
  • [5] Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients
    de la Torre, BR
    Dreher, J
    Malevany, L
    Bagli, M
    Kolbinger, M
    Omran, H
    Lüderitz, B
    Rao, ML
    [J]. THERAPEUTIC DRUG MONITORING, 2001, 23 (04) : 435 - 440
  • [6] Feighner JP, 1995, J CLIN PSYCHIAT, V56, P574
  • [7] FERRIS RM, 1983, J CLIN PSYCHIAT, V44, P74
  • [8] *GLAXOSMITHKLINE, 2002, WELLB SR BUPR HYDR S
  • [9] Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms
    Jain, AK
    Kaplan, RA
    Gadde, KM
    Wadden, TA
    Allison, DB
    Brewer, ER
    Leadbetter, RA
    Richard, N
    Haight, B
    Jamerson, BD
    Buaron, KS
    Metz, A
    [J]. OBESITY RESEARCH, 2002, 10 (10): : 1049 - 1056
  • [10] National Institute of Health National Heart Lung and Blood Institute, 1997, NIH PUBLICATION, V98-4080